大幅缩短审评时限，上海发新政推动创新药发展

Group 1 - Shanghai has issued measures to promote high-quality development in the pharmaceutical industry, including reducing the clinical trial review and approval time for innovative drugs to 30 working days [1] - The integration of China's drug review technical requirements with international standards allows for more participation in the formulation and implementation of global rules, enabling simultaneous application for new drug listings in China and abroad [1] - Companies with strong financial capabilities and rich R&D pipelines are expected to benefit significantly from the optimized review and approval processes [1] Group 2 - The innovative drug sector is anticipated to perform well in terms of revenue and profit, driven by accelerated new drug listings and ongoing business development (BD) transactions [1] - National Investment Securities predicts multiple overseas licensing BD transactions for domestic innovative drugs in the fourth quarter of 2025, indicating a promising outlook for the innovative drug market [2] Group 3 - Hongbo Pharmaceutical, a local Shanghai company, operates in small molecule innovative drug CRO, CDMO, CMO, and commercial production, and has developed an AI drug design platform [3] - Shanghai Yizhong focuses on the R&D, production, and sales of anti-tumor innovative drugs, with its main product being injectable paclitaxel polymer micelles [3]